Published in Int J Nanomedicine on January 01, 2007
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev (2009) 3.17
Magnetite Nanoparticles for Medical MR Imaging. Mater Today (Kidlington) (2011) 1.26
Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomedicine (2015) 1.02
Surface functionalization of magnetic iron oxide nanoparticles for MRI applications - effect of anchoring group and ligand exchange protocol. Contrast Media Mol Imaging (2010) 0.99
Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes. Int J Nanomedicine (2012) 0.98
Block copolymer cross-linked nanoassemblies improve particle stability and biocompatibility of superparamagnetic iron oxide nanoparticles. Pharm Res (2012) 0.94
A new nano-sized iron oxide particle with high sensitivity for cellular magnetic resonance imaging. Mol Imaging Biol (2011) 0.94
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev (2015) 0.92
Application of nanoparticles on diagnosis and therapy in gliomas. Biomed Res Int (2013) 0.91
Iron nanoparticles increase 7-ketocholesterol-induced cell death, inflammation, and oxidation on murine cardiac HL1-NB cells. Int J Nanomedicine (2010) 0.90
Detection of MUC1-expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging. ScientificWorldJournal (2013) 0.88
Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging. Neuro Oncol (2011) 0.85
Impact of surface coating and particle size on the uptake of small and ultrasmall superparamagnetic iron oxide nanoparticles by macrophages. Int J Nanomedicine (2012) 0.85
Multifunctional materials for bone cancer treatment. Int J Nanomedicine (2014) 0.84
Certain types of iron oxide nanoparticles are not suited to passively target inflammatory cells that infiltrate the brain in response to stroke. J Cereb Blood Flow Metab (2013) 0.83
A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer. Int J Nanomedicine (2012) 0.83
Essential Elements to Consider for MRI Cell Tracking Studies with Iron Oxide-based Labeling Agents. J Basic Clin Med (2012) 0.82
Noninvasive imaging of atheromatous carotid plaques. Nat Clin Pract Cardiovasc Med (2009) 0.82
Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide. J Cardiovasc Magn Reson (2015) 0.79
Molecular characterization of rheumatoid arthritis with magnetic resonance imaging. Top Magn Reson Imaging (2011) 0.79
Experimental bladder regeneration using a poly-l-lactide/silk fibroin scaffold seeded with nanoparticle-labeled allogenic bone marrow stromal cells. Int J Nanomedicine (2016) 0.77
Enhanced MRI T 2 Relaxivity in Contrast-Probed Anchor-Free PEGylated Iron Oxide Nanoparticles. Nanoscale Res Lett (2017) 0.75
Aptamer-PEG-modified Fe3O4@Mn as a novel T1- and T2- dual-model MRI contrast agent targeting hypoxia-induced cancer stem cells. Sci Rep (2016) 0.75
Tuning the growth pattern in 2D confinement regime of Sm2O3 and the emerging room temperature unusual superparamagnetism. Sci Rep (2014) 0.75
Enhanced magnetic resonance imaging and staining of cancer cells using ferrimagnetic H-ferritin nanoparticles with increasing core size. Int J Nanomedicine (2015) 0.75
pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas. Bioconjug Chem (2016) 0.75
Current Status and Future Direction of Nanomedicine: Focus on Advanced Biological and Medical Applications. Nucl Med Mol Imaging (2016) 0.75
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials (2005) 11.01
Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev (2005) 10.41
Formation and Structure of Self-Assembled Monolayers. Chem Rev (1996) 6.35
Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev (2006) 4.69
Synthesis of highly crystalline and monodisperse maghemite nanocrystallites without a size-selection process. J Am Chem Soc (2001) 4.28
Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology (1990) 3.50
Recent advances in the liquid-phase syntheses of inorganic nanoparticles. Chem Rev (2004) 3.14
Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials (2002) 3.12
Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. J Immunol Methods (1982) 2.16
Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol (2004) 2.13
Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem (2005) 1.99
Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med (2002) 1.95
Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol (2006) 1.77
Synthesis of Iron Oxide Nanoparticles Used as MRI Contrast Agents: A Parametric Study. J Colloid Interface Sci (1999) 1.74
Transverse relaxation of solvent protons induced by magnetized spheres: application to ferritin, erythrocytes, and magnetite. Magn Reson Med (1987) 1.62
Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J Drug Target (1998) 1.53
Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging (1995) 1.38
Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm (2000) 1.35
Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol (2004) 1.26
Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol (2004) 1.18
Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience. Radiology (1998) 1.17
Thiolation of Maghemite Nanoparticles by Dimercaptosuccinic Acid J Colloid Interface Sci (1997) 1.12
Toward the syntheses of universal ligands for metal oxide surfaces: controlling surface functionality through click chemistry. J Am Chem Soc (2006) 1.06
Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol (1998) 1.02
Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Des (2005) 1.01
Effects of surface coordination chemistry on the magnetic properties of MnFe(2)O(4) spinel ferrite nanoparticles. J Am Chem Soc (2003) 0.98
Absolute Aggregation Rate Constants of Hematite Particles in Aqueous Suspensions: A Comparison of Two Different Surface Morphologies. J Colloid Interface Sci (1997) 0.98
Synthesis of ultrasmall superparamagnetic iron oxides using reduced polysaccharides. Bioconjug Chem (2004) 0.97
Adsorptive removal of phosphate from aqueous solutions using iron oxide tailings. Water Res (2004) 0.94
Titanium implant materials with improved biocompatibility through coating with phosphonate-anchored cyclic RGD peptides. Chembiochem (2005) 0.94
Structure and Bonding of Orthophosphate Ions at the Iron Oxide-Aqueous Interface. J Colloid Interface Sci (1996) 0.93
Stabilization of magnetorheological suspensions by polyacrylic acid polymers. J Colloid Interface Sci (2005) 0.92
Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. Int J Pharm (2006) 0.90
Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects. Top Magn Reson Imaging (1998) 0.90
Two-time window and multiangle photon correlation spectroscopy size and zeta potential analysis--highly sensitive rapid assay for dispersion stability. J Pharm Sci (2000) 0.84
Streaming potential in open and packed fused-silica capillaries. J Chromatogr A (2002) 0.84
Preparation and characterization of carbonyl iron/poly(butylcyanoacrylate) core/shell nanoparticles. J Colloid Interface Sci (2006) 0.84
Hydrodynamics within the electric double layer on slipping surfaces. Phys Rev Lett (2004) 0.84
Colloidal stability of magnetite/poly(lactic acid) core/shell nanoparticles. Langmuir (2006) 0.84
Iron oxide-enhanced MR lymphography: initial experience. Eur J Radiol (2000) 0.83
An evaluation of the contributions of diffusion and exchange in relaxation enhancement by MRI contrast agents. J Magn Reson (2002) 0.83
Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release (2001) 0.83
Aging effects in the electrokinetics of colloidal iron oxides. J Colloid Interface Sci (2002) 0.83
Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck. AJNR Am J Neuroradiol (1994) 0.81
Colloidal stability of aqueous polymeric dispersions: effect of pH and salt concentration. Colloids Surf B Biointerfaces (2005) 0.81
Structural characterization of complexes between iminodiacetate blocked on styrene-divinylbenzene matrix (Chelex 100 resin) and Fe(III), Cr(III), and Zn(II) in solid phase by energy-dispersive X-ray diffraction. J Am Chem Soc (2001) 0.81
Structure of polymer-stabilized magnetic fluids: small-angle neutron scattering and mean-field lattice modeling. Langmuir (2004) 0.80
Ferumoxtran-10 Advanced Magnetics. IDrugs (2003) 0.80
Aminomethylphosphonic acid and glyphosate adsorption onto goethite: a comparative study. Environ Sci Technol (2005) 0.79
Structural characterization of ultrasmall superparamagnetic iron oxide (USPIO) particles in aqueous suspension by energy dispersive X-ray diffraction (EDXD). J Am Chem Soc (2006) 0.78
Adsorption of Phosphonates onto the Goethite-Water Interface. J Colloid Interface Sci (1999) 0.77
Structural analysis of the solid amorphous binuclear complexes of iron(III) and aluminum(III) with chromium(III)-DTPA chelator using energy dispersive X-ray diffraction. J Am Chem Soc (2002) 0.77
Pre-clinical results with Clariscan (NC100150 Injection); experience from different disease models. MAGMA (2001) 0.77
Colloidal Stability of Polymer Colloids with Different Interfacial Properties: Mechanisms J Colloid Interface Sci (1996) 0.77
Evidence for the Validity of Electrokinetic Theory in the Thin Double Layer Region J Colloid Interface Sci (1996) 0.76
Chemical force microscopy investigation of phosphate adsorption on the surfaces of iron(III) oxyhydroxide particles. J Colloid Interface Sci (2002) 0.76
Colloidal Stability of Polymer Colloids with Variable Surface Charge. J Colloid Interface Sci (1999) 0.76
Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev (2008) 8.23
Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev (2002) 7.05
Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev (2006) 4.69
Stimuli-responsive nanocarriers for drug delivery. Nat Mater (2013) 3.52
Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci (2009) 2.63
Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater (2009) 2.43
Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev (2012) 2.26
Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem (2005) 1.99
Metal-organic frameworks in biomedicine. Chem Rev (2011) 1.93
Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol (2006) 1.48
Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev (2013) 1.43
Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol (2008) 1.41
Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol (2005) 1.38
Squalenoyl nanomedicines as potential therapeutics. Nano Lett (2006) 1.28
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev (2003) 1.25
Squalene: A natural triterpene for use in disease management and therapy. Adv Drug Deliv Rev (2009) 1.25
Dynamic study of blood-brain barrier closure after its disruption using ultrasound: a quantitative analysis. J Cereb Blood Flow Metab (2012) 1.21
Nanotheranostics for personalized medicine. Adv Drug Deliv Rev (2012) 1.19
BioMOFs: metal-organic frameworks for biological and medical applications. Angew Chem Int Ed Engl (2010) 1.16
Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials (2003) 1.15
Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther (2002) 1.12
Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials (2006) 1.12
Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol Pharm (2009) 1.09
Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm (2004) 1.08
A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release (2007) 1.06
Effect of nanoparticle and aggregate size on the relaxometric properties of MR contrast agents based on high quality magnetite nanoparticles. J Phys Chem B (2009) 1.03
Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem (2005) 1.03
A high-frequency EPR study of frozen solutions of Gd(III) complexes: straightforward determination of the zero-field splitting parameters and simulation of the NMRD profiles. J Am Chem Soc (2006) 1.02
"Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev (2004) 1.01
Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Des (2005) 1.01
A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci (2009) 1.01
Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging (2009) 1.01
Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis (2007) 1.00
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc Natl Acad Sci U S A (2014) 1.00
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine (2011) 0.99
Novel approaches to deliver gemcitabine to cancers. Curr Pharm Des (2008) 0.99
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine (2011) 0.98
Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology (2008) 0.98
Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm (2007) 0.98
Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol (2004) 0.98
Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Control Release (2004) 0.98
Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem (2012) 0.97
Hydrogels incorporating GdDOTA: towards highly efficient dual T1/T2 MRI contrast agents. Angew Chem Int Ed Engl (2012) 0.97
Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res (2006) 0.96
Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol. Invest Radiol (2003) 0.96
Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting. Langmuir (2008) 0.95
Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm (2005) 0.95
Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci (2002) 0.95
Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target (2009) 0.95
Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. ACS Nano (2011) 0.94
Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am (2009) 0.94
Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol (2011) 0.94
In vivo CEST MR imaging of U87 mice brain tumor angiogenesis using targeted LipoCEST contrast agent at 7 T. Magn Reson Med (2012) 0.93
Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol (2012) 0.93
Role of gut macrophages in mice orally contaminated with scrapie or BSE. Int J Pharm (2005) 0.93
Recent advances in superparamagnetic iron oxide nanoparticles for cellular imaging and targeted therapy research. Curr Pharm Des (2013) 0.92
Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules (2007) 0.92
Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int J Nanomedicine (2010) 0.92
Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano (2012) 0.91
Study of emulsion stabilization by graft copolymers using the optical analyzer Turbiscan. Int J Pharm (2003) 0.90
Ultrasmall iron oxide nanoparticles for biomedical applications: improving the colloidal and magnetic properties. Langmuir (2011) 0.90
Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci (2002) 0.90
Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery. Acc Chem Res (2010) 0.90
Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J Med Chem (2011) 0.90
Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol (2011) 0.90
Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. Int J Pharm (2006) 0.90
A new paradigm for high-sensitivity 19F magnetic resonance imaging of perfluorooctylbromide. Magn Reson Med (2010) 0.89
Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther (2008) 0.89
Magnetic resonance molecular imaging of vascular cell adhesion molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe. J Med Chem (2009) 0.89
Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm Res (2003) 0.88
Squalenoylation: a generic platform for nanoparticular drug delivery. J Control Release (2011) 0.88
Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos (2008) 0.88
Cationic vectors in ocular drug delivery. J Drug Target (2004) 0.87
19F molecular MR imaging for detection of brain tumor angiogenesis: in vivo validation using targeted PFOB nanoparticles. Angiogenesis (2012) 0.87
Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol Pharm (2009) 0.87
A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int J Pharm (2005) 0.87
PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. ACS Nano (2012) 0.86
Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging. Chem Commun (Camb) (2010) 0.86
Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. Toxicol Sci (2012) 0.85
Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chem Phys Lipids (2004) 0.85
Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier. Biomaterials (2004) 0.84
In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates. Mol Pharm (2012) 0.84
Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J Control Release (2006) 0.84
Biological characterization of folic acid-conjugated poly(H2NPEGCA-co-HDCA) nanoparticles in cellular models. J Drug Target (2007) 0.84
Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Res (2011) 0.84